The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.
about
Advances in Lipidomics for Cancer Biomarkers DiscoveryFine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility lociComparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate CellsLysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinomaSystemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues.Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformaticsGlycerophosphate/Acylglycerophosphate acyltransferases.A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.Overexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer.FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cellsDecreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.Phospholipids as cancer biomarkers: Mass spectrometry-based analysis.Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.Integrated analysis of long noncoding RNA and coding RNA expression in esophageal squamous cell carcinoma.Anti-melanoma activity of Forsythiae Fructus aqueous extract in mice involves regulation of glycerophospholipid metabolisms by UPLC/Q-TOF MS-based metabolomics study.Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice.Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells.The role of phosphatidylcholine and choline metabolites to cell proliferation and survival.Generation of membrane diversity by lysophospholipid acyltransferases.High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS.Elevated expression of notch1 is associated with metastasis of human malignancies.Comparison of hepatic and serum lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and prognostic biomarkers.Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
P2860
Q28079507-A0E86F16-EE85-40C7-9906-CA55687F0A1CQ28384269-8C907370-9364-49A0-849A-688532A22AE9Q28547040-47D9FF07-E4E4-4E8E-B770-BE7DC1E42F22Q33667501-3F1ACB73-3680-43E6-BC5A-B7B2172C7178Q34255382-F3725ABE-C68E-403D-BEA5-4FBA1D80DD73Q34477513-BCBD9718-815C-4118-9EF7-61C32D6A5818Q34792406-DD32AAF6-7070-4603-8925-48ECC2E0A6D2Q35112837-23FCCFC3-89EF-46F0-AB1B-7447DED448ACQ35214355-F0ED3F08-C284-46DF-A844-8C5BBD17FC3FQ35573943-BB4FAEBD-040C-4321-B495-C1E77C6A00CDQ35742526-82BA9BC6-3234-410A-90F5-EFC59EF683A8Q35762498-FCF17D2A-D637-494A-8863-F23E44ABD463Q36045221-F7FCC603-82EF-49B4-B0DD-166DB306CBB7Q37156655-0E36567D-023D-4766-A846-EBF029D8C87FQ37270399-B417B96B-EB65-477C-895B-089E524B625FQ37519196-D2AE0366-4CBC-4116-B351-83A0592E2695Q37660266-08A253A9-B759-4CEA-B25F-E0D4CD402AF6Q37671074-A4170D84-9B84-420A-B94C-385EBA414590Q37716341-BA9D339C-EC99-4669-9D00-DDE70E04810FQ38076754-C998C951-966D-4566-BC1D-C9F49CB23D4EQ38108686-8CA0783C-9FBC-434A-BCDC-F6E31AACA932Q41134388-70023481-5F4A-41A4-9900-D42960BCE913Q42249705-BFF26F1A-1E85-4B36-85F9-C9BF5712EE1AQ43900208-0DEC435E-DBC4-42BD-9616-5BB2F6BE6758Q50052924-5926E797-18FE-4F0A-AAC7-139947F32C03Q53809263-3A730D7C-6C02-491C-B8CD-B09F3B831A35
P2860
The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The expression level of lysoph ...... rogression of prostate cancer.
@en
The expression level of lysophosphatidylcholine acyltransferase 1
@nl
type
label
The expression level of lysoph ...... rogression of prostate cancer.
@en
The expression level of lysophosphatidylcholine acyltransferase 1
@nl
prefLabel
The expression level of lysoph ...... rogression of prostate cancer.
@en
The expression level of lysophosphatidylcholine acyltransferase 1
@nl
P2093
P2860
P1476
The expression level of lysoph ...... rogression of prostate cancer.
@en
P2093
Charles R Pound
Jinghe Mao
Steven A Bigler
Thomas J Lawrence
Xinchun Zhou
P2860
P304
P356
10.1016/J.YEXMP.2011.11.001
P577
2011-11-11T00:00:00Z